Adaptive Biotechnologies Corp (ADPT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through two operating segments: Minimal Residual Disease (MRD), focused on the clonoSEQ diagnostic test, and Immune Medicine, focused on drug discovery and the collaboration with Genentech. The company operates as a large accelerated filer.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $46.4 million | $37.9 million | $131.5 million | $124.5 million |
| Net Loss (GAAP) | $(32.1) million | $(50.3) million | $(125.8) million | $(155.8) million |
| Net Loss Per Share | $(0.22) | $(0.35) | $(0.86) | $(1.08) |
| Adjusted EBITDA | $(14.3) million | $(29.8) million | $(63.9) million | $(91.7) million |
| Cash & Marketable Securities | $267.2 million | $346.4 million (Dec 2023) | N/A | N/A |
| Revenue Interest Liability | $132.7 million | $130.7 million (Dec 2023) | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22% in Q3 and 6% YTD. MRD revenue grew 52% in Q3 (driven by a $5.0 million regulatory milestone and 30% increase in clonoSEQ test volume), while Immune Medicine revenue declined 32% in Q3 due to lower collaboration revenue from Genentech.
- Expense Reduction: Operating expenses decreased 11% in Q3 and 7% YTD. Research and Development (R&D) expenses dropped 15% in Q3, primarily due to reduced personnel costs and decreased investment in drug discovery efforts.
- Restructuring & Impairment: The company recognized $7.2 million in impairment charges during the nine months ended September 30, 2024, related to vacating leased space in South San Francisco and halting certain software enhancements. Total restructuring costs for the period were $9.1 million.
- Liquidity: Cash, cash equivalents, and marketable securities decreased from $346.4 million at year-end 2023 to $267.2 million at September 30, 2024, reflecting operating cash outflows of $82.7 million YTD.
Guidance, Outlook, and Risks
- Outlook: Management expects MRD revenue to increase long-term through expanded patient populations and payor coverage. Immune Medicine revenue is expected to grow as therapies advance to commercialization, though it may fluctuate based on Genentech collaboration expenses and milestone timing.
- Liquidity Position: The company believes existing cash and marketable securities are sufficient to fund operations for at least the next 12 months. They have access to up to an additional $125.0 million under their Revenue Interest Purchase Agreement with OrbiMed, subject to conditions.
- Risks: Key risks include reliance on the Genentech collaboration, the novelty of immune medicine, regulatory approval uncertainties for partner therapeutics, and the need for future capital raises which could result in dilution.
- Unusual Items: The $7.2 million impairment charge and $9.1 million in restructuring costs are non-recurring items impacting the current period's net loss.
Investor Verification Checklist
- Genentech Collaboration: Verify the sustainability of Immune Medicine revenue given the 71% YTD decline in collaboration revenue and the dependency on Genentech's development milestones.
- Restructuring Completion: Confirm that the $9.1 million in restructuring costs are fully recognized and that the anticipated cost savings from laboratory consolidation are materializing.
- Revenue Interest Liability: Review the effective interest rate (8.8% as of Q3 2024) and the assumptions regarding the repayment timeline of the OrbiMed agreement, as changes here directly impact interest expense.
- MRD Test Volume: Validate the 30% Q3 and 35% YTD growth in clonoSEQ test volumes to ensure organic growth is offsetting the decline in collaboration revenue.
- Cash Burn Rate: Assess the $82.7 million operating cash burn YTD against the $267.2 million cash balance to determine the runway without additional financing.